Australian Clinical Labs Ltd · ASX:ACL
Australian Clinical Labs — Shareholder Meeting (October 2026)
32 slides from Australian Clinical Labs's shareholder meeting presentation, Oct 28, 2026
Slide 1: ASX Announcement – Annual General Meeting 2026
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia For personal use only clinicallabs.com.au Wednesday, 28 October 2026 AUSTRALIAN CLINICAL LABS LIMITED – ANNUAL GENERAL MEETING 2026 Australian Clinical Labs Lim
Slide 2: Order of Proceedings
2026 ANNUAL GENERAL MEETING OF ACL Order of Proceedings For personal use only Good afternoon everyone and welcome to ACL’s 2026 AGM. My name is Stephen Roche and I have the privilege of being the Chair of your Board. We, Australian Clinical Labs, would like to acknowledge the traditional Aboriginal
Slide 3: For personal use only
need to register by clicking on the Get A Voting Card button and providing your security holder number and postcode. If you are an appointed proxy, please enter the proxy number issued by MUFG in the proxy details section. Once you have registered, your For personal use only voting card will appear
Slide 4: For personal use only
Despite these conditions, ACL delivered a resilient financial performance. Underlying EBIT increased to $69.2 million. Earnings per share increased year on year by 8.5%. Return on invested capital improved to greater than 25%, and the company generated For personal use only strong operational cash f
Slide 5: For personal use only
and the long-term capability of the sector. The board and management will continue to advocate constructively for government funding arrangements that recognise both the clinical importance and the underlying cost of delivering high-quality pathology For personal use only services. Nevertheless, ACL
Slide 6: For personal use only
decade of outstanding service, Melinda McGrath concluded her tenure as Group Chief Executive Officer and Executive Director. Under Melinda's leadership, ACL integrated multiple pathology businesses, established a national operating platform, completed For personal use only its ASX listing, and succe
Slide 7: Speaker: Greg Horan
SPEAKER: GREG HORAN ------------------------ Thank you, Stephen. Good afternoon, and thank you for participating in our AGM for For personal use only 2026. It is a privilege to address shareholders as Chief Executive Officer of Australian Clinical Labs. I would like to begin by acknowledging the con
Slide 8: For personal use only
Our growth agenda is centred on five connected priorities. First is disciplined network and contract growth. We will expand our collection centre network and pursue new contracts where we can deliver appropriate returns. Growth for its own sake is not our For personal use only objective. New locatio
Slide 9: For personal use only
approach to profitable growth and operational excellence. The company's investment case does not depend on a rapid recovery in the pathology For personal use only market. We are focused on the levers within our control, reliable service delivery, stronger referrer engagement, disciplined account man
Slide 10: For personal use only
underlying EBIT of between $67 million and $73 million. And with the improved growth, we're expecting to be at the higher end of the guidance. This represents an implied EBIT margin of approximately 9% to 9.5%. For personal use only The guidance reflects continued wage pressure and known funding set
Slide 11: Welcome to our FY26 AGM
rsonal use only Welcome to our FY26 AGM The meeting will begin shortly.
Slide 12: 2026 Annual General Meeting
rsonal use only 2026 Annual General Meeting 28 October 2026
Slide 13: Acknowledgement of Country
3 Acknowledgement of Country rsonal use only We, Australian Clinical Labs Limited, would like to acknowledge the traditional Aboriginal and Torres Strait Islander Custodians of the unceded land on which we work and deliver our services. We pay our respect to Elders past and present as the holders of
Slide 14: Introduction
4 Introduction rsonal use only Christine Bartlett Mark Haberlin Stephen Roche Independent Non- Independent Non- Executive Director Executive Director Board Chair Chair of People and Chair of Audit and Culture Committee Risk Committee Sarah Butler Dr Amandeep Hansra Greg Horan Independent Non- Indepe
Slide 15: Introduction
5 Introduction rsonal use only Matthew Cordingley Eleanor Padman Chief Financial Officer Company Secretary Ben Powers Pitcher Partners
Slide 16: Shareholder Information – How to vote
6 Shareholder Information rsonal use only How to vote: • Register by clicking on the “Get a Voting Card” button • Click “For”, “Against” or “Abstain” for each resolution • Once you have finished voting on all resolutions, please click “Submit Vote”
Slide 17: Shareholder Information – How to ask a question
7 Shareholder Information rsonal use only How to ask a question • Click on the “Ask a Question” button • Fill in the box and then click submit question
Slide 18: Agenda
8 Agenda rsonal use only 1. Acknowledgement of Country 2. Chair’s Address 3. CEO’s Address 4. Formal business of the meeting including Q&A
Slide 19: Chair's Address
Chair’s Address rsonal use only Stephen Roche Board Chair
Slide 20: FY26 Highlights
10 FY26 Highlights rsonal use only ACL delivered a resilient financial performance in FY26: • Underlying EBIT increased to $69.2 million • Earnings per share increased year on year by 8.5% • Return on invested capital improved to greater than 25% • Generated strong operating cash flow of $64 million
Slide 21: CEO's Address
CEO’s Address rsonal use only Greg Horan Group CEO and Executive Director
Slide 22: FY27 Growth & Performance Priorities
12 FY27 Growth & Performance Priorities rsonal use only 1. Disciplined Network and Contract Growth • Expand the collection centre network and secure new contracts that meet clear strategic, service and financial criteria. 2. Strategic New Business • Pursue opportunities that allow ACL to build on ca
Slide 23: FY27 Trading Update
13 FY27 Trading Update rsonal use only Signs of growth in the Australian pathology market • Medicare data for the first two months of FY27 show national market volumes up 5.8% • An increase in GP attendances are flowing through to pathology referrals • ACL’s specialist pathology referrals have also
Slide 24: Thank you
Thank you AUSTRALIAN @linicalabs
Slide 25: Formal business of the meeting including Q&A
Formal business of the meeting rsonal use only Including Q&A
Slide 26: Resolution: Adoption of the remuneration report
Resolution 1 16 Adoption of the remuneration report rsonal use only “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report of the Company for the financial year ended 30 June 2026 as disclosed in the Directors’ Report be adopted.” Proxy
Slide 27: Resolution: Re-election of Dr Amandeep Hansra
Resolution 2 17 Re-election of Dr Amandeep Hansra rsonal use only “That Dr Amandeep Hansra, having been appointed by the Board as a Director on 1 July 2026 to fill a casual vacancy under rule 6.1(d) of the Company’s Constitution and retiring as a Director of the Company for the purposes of ASX Listi
Slide 28: Resolution: Re-election of Christine Bartlett
Resolution 3 18 Re-election of Christine Bartlett rsonal use only “That Ms Christine Bartlett, retiring as a Director of the Company in accordance with rules 6.1(f)(i)(A) and 6.1(g) of the Company’s Constitution and who has consented to stand for re-election (and being eligible), be re-elected as a
Slide 29: Resolution: Performance rights to Greg Horan
Resolution 4 19 Approval of grant and issue of performance rights to Greg Horan rsonal use only “That approval be given for the purposes of ASX Listing Rule 10.14, and for all other purposes, for the grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, Chief Executive Officer and Ex
Slide 30: Resolution: Reinsertion of proportional takeover provisions
Resolution 5 20 Reinsertion of proportional takeover provisions in the Constitution rsonal use only “That the Proportional Takeover Provisions contained in rule 14 of the Company’s Constitution, having expired on 22 October 2026, be reinserted for a period of three years commencing on the date this
Slide 31: Resolution: Appointment of Deloitte as new auditor
Resolution 6 21 Appointment of Deloitte as new auditor rsonal use only “That, for the purposes of sections 327B(1) Corporations Act 2001 and for all other purposes, Deloitte Touche Tohmatsu, having been nominated by a shareholder pursuant to section 328B Corporations Act 2001, and being qualified an
Slide 32: Thank you and goodbye
rsonal use only Thank you and goodbye
Australian Clinical Labs — Shareholder Meeting (October 2026) on 6ix